In the field of brain-computer interfaces (BCI), Australian company Synchron is making waves with its innovative solution called Stentrode. While Elon Musk's Neuralink has garnered significant attention, Synchron's Stentrode offers a distinct advantage by enabling patients to control their computers without the need for open brain surgery.

Unlike Neuralink, which requires invasive procedures, Stentrode can be inserted into a patient's skull through blood vessels using a catheter. The Stentrode is a tiny mesh, resembling a stent, that contains electrodes capable of picking up brain signals and interpreting them as commands, such as mouse clicks. This groundbreaking development allows even individuals with severe paralysis to regain control over daily tasks like texting, emailing, shopping, and online banking.

Dr. Christina Maher from Sydney University's Brain and Mind Centre lauds Synchron's advancements, stating that the Australian solution is both more sophisticated and safer due to its non-invasive nature. Maher highlights over 25 scientific articles published by Synchron, underscoring their extensive research and expertise. In contrast, she suggests that Neuralink's emphasis on testing the efficacy and safety of surgical robots, while commercially logical, leaves many unanswered questions about their technology.

While Neuralink successfully implanted a brain chip in its first human patient, Stentrode has also achieved promising results. Synchron showcased a patient with amyotrophic lateral sclerosis (ALS), Graham Felstad, who, through the use of Stentrode, was able to control his computer solely through his thoughts, browsing the internet and texting with friends and family.

The developments by both Neuralink and Synchron, along with several other ongoing projects, offer hope for a better future for individuals affected by severe diseases and injuries. The focus should be on the fulfillment of their mission to improve the lives of those who eagerly await these advancements, rather than on the fame of CEOs or the extent of media coverage. These groundbreaking technologies have the potential to transform the lives of patients in need.